Q-omics provides the consensus-scored PDC profile across patient tissues and cancer cell-line models. PDC expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PDC is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, PDC RNA expression shows 14,046 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KICH, KIRC, and KIRP as cancer lineages where PDC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDC survival associations across molecular data types. PDC RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDC RNA expression–survival associations across cancer types. High PDC expression shows unfavorable associations in KICH, THYM, CHOL, UCEC, SARC and UVM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PDC RNA expression.
This table summarizes PDC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDC shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, READ, LIHC and CHOL. The KIRC box plot shows higher PDC RNA expression in tumor versus normal tissue (log2 FC = +0.062, t-test p < 0.001).
This table shows molecular features associated with PDC in patient tissues and cancer cell lines. In patient samples, PDC shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PDC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
